The Bayer Pharma Data Science & Artificial Intelligence (DS&AI) F2F meeting in Madrid was a great event! The motto Connect, Clarify & Commit came to life as we connected during networking sessions, breakout sessions and social events. At the poster session we learned about our progress embedding a product mindset and driving operational excellence, closely collaborating with our partners across R&D. We heard presentations, took part in discussions, unconference sessions, asked questions and shared ideas, setting foundations for the growth of DS&AI beyond 2023. The use of POAPs was a definite social success and I am sure you did not miss Jesús’ enthusiasm as he gave an overview of this new tool. By promoting its use, we drive new ways of using this sustainable and effective tool, ultimately helping to innovate its use by doctors, within clinical trials, for patients and more. There were fun elements as well, like the final night, where our very own flash-mob took to the dance floor and we danced until way past midnight! All this was made possible by the org team: Anke Ebert, Larsen Schnadhorst, Kathleen Thies, Sheila Elz, Stefanie Holt-Noreiks and Claudia Vogt. They have done an excellent job coordinating the event, with the perfect balance of presentations, speakers, entertainment, and networking. Now let us make sure we continue to further the impact we have on bringing innovative medicines to our patients. Sai Jasti, Head of DS&AI https://bayer.com/poap

Hi, I'm Lucas. Nice to meet you!! My passion is software engineering and music. Check out my band: https://www.excelsis-rockband.de/

I am working in DS3 heading a team working in the areas of Medical Standards, Medical Coding and supporting Data Compliance topics.

Team Data Science Solution & Services Head of Statistics, Analysis & Insights Solutions Living in Cologne, Working in Wuppertal Germany Responsible for Systems like SWAN, TOSCA, BMDA and ALYCE

The SCLM4Future project together with the PRINCE (Preclinical Information Center) project as well as the CONDAS (Connecting Data for Science) team is an excellent example for a successful cross-functional collaboration between CD&O, RED preMed and DS&AI within Research & Development but also between Platform IT and external partners. Together the team achieved to overcome legacy manual processes, redundant maintenance work, and functional silos by introducing new digital solutions and concepts with a strong collaborative mindset. The newly released SCLM 2.0 (Standard Codelist Maintenance) & PTO (Preclinical Terminology and Ontology) systems will enable our organization to improve the quality of controlled terminologies with regards to standard codelists and codes while reducing maintenance time and effort. This will have a positive impact on the code/codelist consistency across clinical and preclinical, as well as the compliance to regulatory requirements (e.g. CDISC (Clinical Data Interchange Standard Consortium) Controlled Terminology). The approach to share our knowledge as well as our efforts across functions will be an important step to archive our goals to increase data quality, interoperability and reusability – or to make a long story short: to make our data even more FAIR. For more information contact: Daniela Bergann.

The Data Assets and Insights Solutions subfunction, DAIS, consists of a team of dedicated computer and data scientists which combine deep R&D process and domain expertise (biology, chemistry, pharmacy, etc) with advanced computational expertise (software engineering, natural language processing, scalable architectures, bio- & chem-informatics, data integration & visualization, etc). We integrate, enrich and harmonize large scientific datasets to build foundational data assets which are used by the R&D organization and our team to build insights solutions. They address key R&D challenges to improve speed, quality and probability of success of our R&D pipeline. Selected business critical tasks within R&D we are focusing on: - Target identification including holistic assessment - Disease understanding including precision medicine - Pipeline evaluation (therapeutic potential and risks) - Modality selection including identification of tool compounds - Identification of collaboration and in-licensing opportunities For more information contact: Wolfgang Thielemann. Artwork: Licensed pictures.

We met during Connect Clarify Commit event in May 2023 in Madrid.